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Abstract:  Hyperglycemia-induced  increase  in  oxidative  stress  is  implicated  in  diabetic 
complications.  This study  investigated the effect of metformin and/or  glibenclamide in 
combination  with  honey  on  antioxidant  enzymes  and  oxidative  stress  markers  in  the 
kidneys of streptozotocin (60 mg/kg; intraperitoneal)-induced diabetic rats. Diabetic rats 
were  randomized  into  eight  groups  of  five  to  seven  rats  and  received  distilled  water  
(0.5 mL); honey (1.0 g/kg); metformin (100 mg/kg); metformin (100 mg/kg) and honey 
(1.0 g/kg); glibenclamide (0.6 mg/kg); glibenclamide (0.6 mg/kg) and honey (1.0 g/kg);  
metformin  (100  mg/kg)  and  glibenclamide  (0.6  mg/kg);  or  metformin  (100  mg/kg), 
glibenclamide  (0.6 mg/kg)  and  honey  (1.0  g/kg)  orally  once  daily  for  four  weeks. 
Malondialdehyde (MDA) levels, glutathione peroxidase (GPx) and superoxide dismutase 
(SOD) activities were significantly elevated while catalase (CAT) activity, total antioxidant 
status (TAS), reduced glutathione (GSH), and GSH:oxidized glutathione (GSSG) ratio was 
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significantly reduced in the diabetic kidneys. CAT, glutathione reductase (GR), TAS, and 
GSH remained significantly  reduced  in  the diabetic rats treated with  metformin  and/or 
glibenclamide. In contrast, metformin or glibenclamide combined with honey significantly 
increased CAT, GR, TAS, and GSH. These results suggest that combination of honey with 
metformin or glibenclamide might offer additional antioxidant effect to these drugs. This 
might reduce oxidative stress-mediated damage in diabetic kidneys.  
Keywords:  diabetes  mellitus;  streptozotocin;  oxidative  stress;  antioxidant  enzymes; 
kidney; tualang honey; metformin; glibenclamide 
 
1. Introduction 
Diabetes mellitus is one of the five main causes of death in the world [1]. The most common form 
of diabetes, which accounts for 90–95% of all diabetic cases, is type 2 diabetes [2]. It is a metabolic 
disorder characterized by hyperglycemia as a result of insulin resistance. This is often followed by  
-cell dysfunction caused by inability of the pancreatic -cells to compensate for the reduced insulin 
action [2]. The global prevalence of diabetes mellitus was estimated as 171 million people in 2000 and 
this figure is predicted to increase to 366 million by 2030 [3]. Besides its severe medical implications, 
this global projection has financial consequences due to the costs of managing this disorder and its 
associated complications. Since diabetes mellitus is a heterogeneous disorder with multiple causes, the 
beneficial  effects  of  combined  therapeutic  agents  aimed  at  specific  patho-biological  pathways  of 
diabetes and its complications have been reported [4,5].  
The  pharmacological  agents  currently  employed,  such  as  sulfonylureas  (e.g.,  glibenclamide), 
biguanides  (e.g.,  metformin),  thiazolidinediones  (e.g.,  pioglitazone)  and  α-glycosidase  inhibitors  
(e.g., acarbose) act to selectively modulate a specific pathological pathway [6,7]. As a result, these 
drugs control blood glucose levels provided they are regularly administered. Even though these drugs 
may be valuable in the management of diabetes mellitus, they have limitations due to undesirable 
adverse effects such as hypoglycemia, weight gain, secondary failure, and inability to arrest pancreas 
degeneration [8–10] or diabetic complications which have been linked to oxidative stress [11]. In view 
of the compelling evidence for a major role of oxidative stress in the development, progression, and 
complications of diabetes, antioxidants may serve as a potential therapy for ameliorating these [12,13]. 
Thus, an ideal therapy for diabetes mellitus would be a drug that not only possesses antihyperglycemic 
effect, but also enhances or protects the antioxidant defense system which is usually compromised. 
Unfortunately, among the currently available hypoglycemic agents, the choice is very limited.  
In our previous studies, we have confirmed the hypoglycemic effect of Malaysian tualang honey as 
well as its antioxidant effect in the kidneys and pancreas of diabetic rats [14,15]. Based on literature, 
no study had investigated the effects of glibenclamide, metformin or both in combination with an 
antioxidant (honey) in the kidneys of experimental diabetic rats. This present study investigated and 
compared  the  role  of  honey  as  an  adjunct  to  metformin  and/or  glibenclamide  in  relation  to  the 
activities of antioxidant enzymes and other markers of oxidative stress in the kidneys of streptozotocin 
(STZ)-induced diabetic rats. Int. J. Mol. Sci. 2011, 12                       
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2. Results and Discussion  
Table  1  shows  the  effects  of  honey,  metformin,  glibenclamide,  and  their  combinations  on  
the  fasting  blood  glucose  and  activities  of  antioxidant  enzymes  in  the  kidneys  of  control  and  
streptozotocin-induced  diabetic  rats.  The  diabetic  control  rats  (without  drugs)  had  significantly 
elevated blood glucose levels compared to the non-diabetic rats. All the drugs significantly decreased 
the levels of blood glucose in diabetic rats. The non-diabetic rats supplemented with honey did not 
show significant changes in the activities of antioxidant enzymes, whereas a significant (p < 0.01) 
decrease  of  catalase  (CAT)  activity  and  increase  of  glutathione  peroxidase  (GPx)  and  superoxide 
dismutase (SOD) were observed in the STZ-treated rats. Treatment of diabetic rats with metformin, 
glibenclamide  or  their  combination  with  honey  significantly  (p  <  0.05)  reduced  SOD  activity. 
Treatment of diabetic rats with metformin or glibenclamide did not produce any significant effects on 
CAT  and  glutathione  reductase  (GR)  activities  compared  to  diabetic  control  rats.  In  contrast, 
metformin or glibenclamide combined with honey showed significantly (p < 0.05) increased CAT and 
GR activities in diabetic rats compared to the diabetic control rats. No significant change in the activity 
of glutathione-S-transferase (GST) was observed in any group. 
Table 1. Effects of honey, metformin, glibenclamide or their combinations on fasting blood 
glucose  and  antioxidant  enzymes  in  the  kidneys  of  control  and  streptozotocin-induced 
diabetic rats. 
Group 
FBG 
(mmol/L) 
SOD  
(U/mg Protein) 
CAT  
(U/mg Protein) 
GPx  
(U/mg Protein) 
GR  
(U/mg Protein) 
GST  
(U/mg Protein) 
Non-diabetic + Distilled water  4.0 (0.9)  1.03 (1.13)  444.2 (89.2)  322.0 (124.9)  208.0 (74.8)  182.5 (50.8) 
Non-diabetic + Honey  3.7 (0.7)  0.96 (0.69)  463.2 (131.8)  326.1 (105.7)  195.9 (38.1)  158.4 (72.1) 
Diabetic + Distilled water  17.9 (2.6) **  2.06 (0.23) *  239.4 (61.6) **  468.7 (47.9) **  175.6 (29.4)  174.0 (30.1) 
Diabetic + Honey  8.8 (5.8) 
†  1.04 (0.45) 
†  347.6 (65.0) 
†  438.7 (93.8)  223.8 (29.3) 
†  185.2 (56.6) 
Diabetic + Metformin  8.4 (6.1) *
,†  1.15 (0.40) 
†  286.5 (76.0)  499.9 (185.5)  213.1 (61.3)  177.9 (73.6) 
Diabetic + Metformin + Honey  8.5 (6.8) *
,†  1.55 (0.64) 
†  341.2 (89.7) 
†  550.5 (80.8)  220.6 (15.1) 
†  172.7 (31.6) 
Diabetic + Glibenclamide  13.5 (10.4) *
,†  1.02 (0.76) 
†  297.7 (149.2)  494.5 (115.6)  223.6 (59.3)  172.0 (64.6) 
Diabetic + Glibenclamide  
+ Honey 
12.3 (6.7) *
,†  1.08 (0.54) 
†  352.7 (54.9) 
†  472.0 (47.1)  239.3 (31.3) 
†  189.2 (41.1) 
Diabetic + Metformin  
+ Glibenclamide 
7.9 (6.5) 
†  0.96 (0.80)  299.3 (49.6)
†  527.2 (91.2)  214.1 (49.4)  173.4 (37.9) 
Diabetic + Metformin  
+ Glibenclamide + Honey 
6.8 (8.4)  1.45 (1.07)  330.6 (80.1)  448.8 (225.3)  200.0 (90.9)  164.7 (96.3) 
Data  are  expressed  as  median  (interquartile  range).  Each  group  consisted  of  5–7  rats.  Groups  were  compared  by  
Kruskal-Wallis  H  test.  Differences  between  two  groups  were  identified  by  Mann-Whitney  U  test  followed  by 
Bonferonni’s correction. Values are statistically significant at * p < 0.05, ** p < 0.01 compared to non-diabetic + distilled 
water; 
†  p  <  0.05  compared  to diabetic  +  distilled  water.  FBG,  fasting  blood  glucose;  SOD,  superoxide dismutase;  
CAT,  catalase;  GPx,  glutathione  peroxidase;  GR,  glutathione  reductase;  GST,  glutathione-S-transferase.  One  unit of  
SOD = the amount of enzyme required to exhibit 50% dismutation of superoxide radical. One unit of CAT = the amount 
of enzyme that catalyzes the decomposition of 1 µ mol of H2O2 per minute. One unit of GPx/GR = the amount of enzyme 
that catalyzes the oxidation of 1 nmol of NADPH per minute. One unit of GST = the amount of enzyme that catalyzes the 
conjugation of 1 nmol of GSH-CDNB per minute.  Int. J. Mol. Sci. 2011, 12                       
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The results of the effects of honey, metformin, glibenclamide and their combinations on markers of 
oxidative stress in the kidneys of control and STZ-induced diabetic rats are shown in Table 2. The 
table  reveals  that  total  antioxidant  status  (TAS),  reduced  glutathione  (GSH)  and  GSH/oxidized 
glutathione  (GSSG)  ratio  were  significantly  (p  <  0.05;  p  <  0.01)  reduced  while  malondialdehyde 
(MDA)  concentrations  were  significantly  (p  <  0.01)  elevated  in  the  STZ-treated  rats  (Table  2). 
Administration  of  honey,  metformin,  glibenclamide  and  their  combinations  to  diabetic  rats 
significantly  (p  <  0.05)  restored  the  levels  of  MDA.  Besides,  all  the  agents  as  well  as  their 
combinations improved GSH/GSSG ratio although not significantly. Combination of metformin or 
glibenclamide with honey significantly (p < 0.05) increased TAS and GSH concentration.  
Table 2. Effects of honey, metformin, glibenclamide or their combinations on markers of 
oxidative stress in the kidneys of control and streptozotocin-induced diabetic rats. 
Group 
TAS 
(nmol/mg 
Protein) 
MDA 
(nmol/mg 
Protein) 
GSH 
(nmol/mg 
Protein) 
GSSG 
(nmol/mg 
Protein) 
GSH/GSSG 
Normal + Distilled water  1.03 (1.19)   1.43 (0.32)   0.140 (0.021)   0.055 (0.015)   2.65 (0.29) 
Normal + Honey  0.97 (1.60)   1.29 (0.62)   0.132 (0.095)   0.049 (0.025)   2.56 (1.05) 
Diabetic + Distilled water  0.52 (0.21) *   2.10 (0.91) **  0.044 (0.012) **  0.047 (0.006)   1.03 (0.95) * 
Diabetic + Honey  0.70 (0.32)   1.02 (0.21) 
†   0.121 (0.043) 
†   0.045 (0.017)   2.49 (1.23) 
Diabetic + Metformin  0.70 (0.15)   1.08 (0.72) 
†   0.140 (0.053) 
†   0.052 (0.015)   2.66 (1.51) 
Diabetic + Metformin + Honey  0.85 (0.09) 
†   1.18 (0.19) 
†   0.117 (0.053) 
†   0.049 (0.028)   1.90 (0.52) 
Diabetic + Glibenclamide  0.80 (0.30)   1.43 (0.59) 
†  0.078 (0.082)   0.043 (0.027)   2.10 (1.54) 
Diabetic + Glibenclamide  
+ Honey 
0.83 (0.27) 
†   1.31 (0.86) 
†  0.116 (0.042) 
†  0.052 (0.052)   2.01 (1.10) 
Diabetic + Metformin  
+ Glibenclamide  
0.73 (0.17)   1.39 (0.26) 
†   0.100 (0.066)   0.037 (0.012)   2.43 (1.47) 
Diabetic + Metformin  
+ Glibenclamide + Honey 
0.78 (0.19)   1.36 (0.78) 
†   0.113 (0.121)  0.049 (0.019)   1.61 (2.25) 
Data  are  expressed  as  median  (interquartile  range).  Each  group  consisted  of  5–7  rats.  Groups  were  compared  by  
Kruskal-Wallis  H  test.  Differences  between  two  groups  were  identified  by  Mann-Whitney  U  test  followed  by 
Bonferonni’s correction. Values are statistically significant at * p < 0.05, ** p < 0.01 compared to non-diabetic + distilled 
water; 
†  p  <  0.05  compared  to  diabetic  +  distilled  water.  TAS,  total  antioxidant  status;  MDA,  malondialdehyde;  
GSH, reduced glutathione; GSSG, oxidized glutathione. 
Figure 1  is  a representative photomicrograph of kidney  sections showing the effects of honey, 
metformin, glibenclamide and their combinations on structural and morphological changes in kidneys 
of control and streptozotocin-induced diabetic rats. The section in Figure 1A is from a non-diabetic 
control  kidney  treated  with  distilled  water  showing  normal  morphological  structures  of  the  renal 
tubules, glomeruli and basement membrane. Figure 1B is a section of a non-diabetic kidney treated 
with tualang honey showing normal renal morphological structures similar to Figure 1A. Figure 1C is 
a section from a diabetic control kidney characterized by necrosis of the epithelium, thickness of the 
glomerular basement membrane and mesangial matrix expansion. Figure 1 (D–J) reveals sections from 
diabetic kidneys treated with tualang honey (D), metformin (E), metformin and tualang honey (F), 
glibenclamide  (G),  glibenclamide  and  tualang  honey  (H),  metformin  and  glibenclamide  (I)  or Int. J. Mol. Sci. 2011, 12                       
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metformin, glibenclamide and tualang honey (J). Figure 1 (D–J) showed less damage, improvement 
and restoration of renal cellular components compared to Figure 1C.  
Figure  1.  Representative  photomicrographs  of  hematoxylin  and  eosin  staining  of  the 
kidney (scale bar: 100 µm) of non-diabetic control rats treated with distilled water (A);  
non-diabetic rats treated with tualang honey (B); diabetic control rats treated with distilled 
water  (C);  diabetic  rats  treated  with  tualang  honey  (D);  diabetic  rats  treated  with  
metformin (E); diabetic rats treated with metformin and tualang honey (F); diabetic rats 
treated  with  glibenclamide  (G);  diabetic  rats  treated  with  glibenclamide  and  tualang  
honey (H); diabetic rats treated with metformin and glibenclamide (I); diabetic rats treated 
with metformin, glibenclamide and tualang honey (J). 
         
         
Figure 2 is a representative photomicrograph which shows sections of the pancreas of control and 
streptozotocin-induced diabetic rats treated with honey, metformin and/or glibenclamide as well as 
their  combinations.  Figure  2A  reveals  a  section  of  normal  pancreas  treated  with  distilled  water 
showing a normal cellular population in the islet of Langerhans. Figure 2B is a section of a normal 
pancreas treated with tualang honey, also showing normal architecture and cellular population, similar 
to in Figure 2A. Figure 2C is a section of a streptozotocin-induced diabetic control pancreas showing 
severe damage to the islet of Langerhans, pancreatic necrosis, reduced islet size, vacuolization and a 
reduced number of cells. Figure 2 (D–J) reveals sections of streptozotocin-induced diabetic pancreas 
treated with tualang honey (D), metformin (E), metformin and tualang honey (F), glibenclamide (G), 
glibenclamide and tualang honey (H), metformin and glibenclamide (I) or metformin, glibenclamide 
and tualang honey (J). In spite of treatment, all these sections—Figure 2 (D–J)—show necrosis of the 
islets of Langerhans, cellular degeneration and a reduced number of cells compared to Figure 2A 
and 2B. However, compared to Figure 2C, these sections—Figure 2 (D–J)—show some improvements Int. J. Mol. Sci. 2011, 12                       
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as characterized by less severe damage, partial restoration of cellular population and enlarged size of 
the islets of Langerhans. 
Figure 2. Representative photomicrographs of hematoxylin and eosin staining of pancreas 
(scale bar: 100 µm) showing  non-diabetic control rats treated  with distilled water (A);  
non-diabetic rats treated with tualang honey (B); diabetic control rats treated with distilled 
water  (C);  diabetic  rats  treated  with  tualang  honey  (D);  diabetic  rats  treated  with  
metformin (E); diabetic rats treated with metformin and tualang honey (F); diabetic rats 
treated  with  glibenclamide  (G);  diabetic  rats  treated  with  glibenclamide  and  tualang  
honey (H); diabetic rats treated with metformin and glibenclamide (I); diabetic rats treated 
with metformin, glibenclamide and tualang honey (J).  
         
         
 
In view of the fact that diabetes is a disorder of multiple defects, monotherapy with hypoglycemic 
agents which target a specific pathological condition may not be effective. This perhaps contributes to 
the increased morbidity and mortality associated with this disorder. Based on current literature, it is 
noteworthy that this is the first study which investigates and compares the effect of an antioxidant 
(honey) in combination with glibenclamide, metformin or glibenclamide + metformin on antioxidant 
enzymes and other markers of oxidative stress in kidneys of STZ-induced diabetic rats.  
Lipid peroxidation, measured as malondialdehyde (MDA), reflects the impact of oxidative stress in 
cells  and  tissues.  In  diabetes,  insulin  deficiency  enhances  the  activity  of  fatty  acyl  Coenzyme  A 
oxidase,  an  enzyme  that  causes  oxidation  of  fatty  acids,  leading  to  increased  hydrogen  peroxide 
formation [16]. Peroxides, including hydrogen peroxide, are known to exert detrimental effects on 
proteins, lipids, and polyunsaturated fatty acids (PUFAs) of cellular membranes. These deleterious 
effects can occur directly and/or indirectly through the formation of highly reactive hydroxyl radical or 
reaction with transition ions such as copper or iron to form toxic aldehydes [17]. Lipid peroxidation 
products  are  also  vulnerable  to  radicals,  thus  further  propagating  free  radical  generation  and Int. J. Mol. Sci. 2011, 12                       
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contributing  to  oxidative  damage  [18].  They  can  also  damage  deoxyribonucleic  acid  (DNA)  by 
forming  cross  links  with  it  [19].  In  this  study,  renal  MDA  concentrations  in  diabetic  rats  were 
significantly elevated. This is similar to what was previously reported [14]. The increased MDA levels 
suggest the occurrence of lipid oxidative damage which is implicated in the development of diabetic 
nephropathy  [18].  Treatment  with  glibenclamide,  metformin,  honey,  and  their  combinations 
significantly  reduced  the  levels  of  MDA.  These  findings  suggest  that  these  agents  exhibit  
anti-peroxidative effect. This may be due to their hypoglycemic effect as previously reported and also 
antioxidant properties in the case of tualang honey [7,14,20,21]. 
The measurement of total antioxidant status (TAS) indicates the total summation of the individual 
enzymatic and non-enzymatic antioxidants present in a sample [22]. Thus, TAS may be altered during 
oxidative  stress.  The  reduced  TAS  in  the  untreated  diabetic  rats  might  imply  that  there  was  an 
imbalance  between  free  radical  formation  and  renal  antioxidant  protection.  This  might  be  a 
consequence of increased utilization of renal endogenous antioxidants in response to elevated levels of 
free radicals. Our data showed that none of the hypoglycemic agents elevated TAS. On the other hand, 
combination  of metformin or glibenclamide  with tualang honey  significantly increased TAS.  This 
might demonstrate that tualang honey offered additional antioxidant effect to these drugs. 
Glutathione, an important intracellular free radical scavenger and co-substrate for many important 
enzymes, plays a prominent role in the degradation of hydrogen peroxide undergoing oxidation from 
its reduced form (GSH) to an oxidized state (GSSG) [23]. The ratio of GSH to GSSG often reflects 
cellular redox balance. A low level of GSH is reported in diabetes mellitus [13]. The reduced levels of 
GSH and GSH/GSSG ratio of the diabetic rats would indicate that the renal glutathione defense system 
was significantly compromised. The high levels of MDA in the diabetic rats might also contribute to 
the impaired glutathione defenses [13]. In view of the fact that GSH content, GSH/GSSG ratio, and 
TAS are all indicators for antioxidant capacity of a tissue to protect itself against oxidative stress and 
damage  caused  by  free  radicals,  it  could  be  inferred  that  the  kidneys  of  diabetic  rats  are  highly 
vulnerable to oxidative stress as reported in this study and others [24,25]. Our results showed that, 
unlike metformin or honey, glibenclamide did not produce any effect on GSH or GSH/GSSG ratio. 
However, in combination with tualang honey, glibenclamide increased GSH. Hence, this suggests the 
beneficial effect of tualang honey on glibenclamide.  
Our results showed that superoxide dismutase (SOD) activity was increased while catalase (CAT) 
activity was reduced in the kidneys of STZ-induced diabetic rats. There are conflicting results with 
regard to SOD or CAT status in diabetes. Some studies reported reduced activities of these enzymes 
while others found increase [13]. Treatment with antioxidants such as α-lipoic acid, vitamins C and E 
was  reported  to  reverse  the  activities  of  these  enzymes  while  in  other  studies  no  changes  were 
observed  with  antioxidant  treatment  [13].  Diabetes  mellitus  is  often  characterized  by  chronic 
hyperglycemia [2]. In the mitochondria, the excessive levels of glucose lead to an overdrive of the 
electron transport chain, resulting in the formation of excess superoxide anions [26]. Thus, the elevated 
blood glucose in the diabetic control rats might enhance production of superoxide radical. Oxidative 
stress ensues when SOD, which normally scavenges superoxide, becomes overwhelmed. The role of 
SOD  is  certainly  important  in  the  regulation  of  oxidative  stress  in  diabetes  mellitus.  Therefore, 
increased SOD activity might be a response to increased generation of superoxide anions. Enhanced 
activity of antioxidant enzymes has been reported as an adaptive mechanism to protect cells against the Int. J. Mol. Sci. 2011, 12                       
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toxicity of free radicals [27]. Since SOD converts superoxide anions to hydrogen peroxide (H2O2), 
enhanced  SOD  activity  might  lead  to  increased  turnover  of  H2O2.  Normally,  H2O2  is  further 
metabolized to H2O and O2 by CAT. CAT, being an endogenous antioxidant enzyme, will need to be 
replenished. However, in the event of increased generation of H2O2, CAT might be unable to scavenge 
sufficiently the high levels of H2O2 and thus become inhibited. Besides, CAT is reported to be highly 
susceptible  to  increased  superoxide  anions  [28].  Therefore,  all  these  might  be  responsible  for  the 
reduced activity of CAT observed in the diabetic kidney. 
Glutathione peroxidase (GPx) plays an important role in the metabolism of hydrogen and lipid 
peroxides by  using  reduced  glutathione (GSH)  as a hydrogen donor  resulting in the  formation of 
oxidized glutathione (GSSG) [23]. On the other hand, glutathione reductase (GR) helps to regenerate 
glutathione  by  recycling  GSSG  back  to  GSH  using  NADPH  as  a  co-factor  [23].  In  diabetes, 
glutathione  peroxidase  activity  is  reported  to  be  increased  in  many  tissues  including  kidney  [13]. 
Treatment with antioxidants such as piperine restored GPx activity while boldine or quercetin did  
not  [13].  In  this  study,  GPx  activity  was  significantly  increased  while  GR  activity  was  reduced 
insignificantly in diabetic kidneys. The increased GPx activity might be a consequence of increased 
H2O2 generated by enhanced SOD activity. This is often a compensatory mechanism to protect tissues 
against  toxic  effect  of  organic  and  inorganic  peroxides  including  excess  H2O2  [29].  The  reduced 
activity of GR may indicate the inability of the diabetic kidneys to effectively regenerate GSH from 
GSSG.  This  impaired  recycling  of  GSSG  to  GSH  might  contribute  to  low  levels  of  GSH  and 
GSH/GSSG ratio in the diabetic rats. Michiels and his colleagues have showed that the protection  
of  cells  against  oxidative  stress  and  damage  is  more  effective  when  antioxidant  enzymes  act  
together [30]. Therefore, the occurrence of uncoordinated activities of these antioxidant enzymes in the 
diabetic kidneys might imply that the diabetic rats were not protected against oxidative stress. Even 
though GPx activity remained increased in all the treated rats, the beneficial effect of tualang honey in 
combination with metformin or glibenclamide on CAT activity might contribute in reducing excess 
H2O2  levels.  This  beneficial  effect  on  these  drugs  might  be  responsible  for  the  increased  GSH,  
TAS and GR. 
As previously reported, both the kidneys and pancreas of diabetic rats are subject to oxidative  
stress  [14,15,31].  This  present  study  suggests  that  metformin  or  glibenclamide  might  ameliorate 
oxidative stress in the kidneys of diabetic rats to a certain extent with regard to SOD and MDA. 
However, these drugs do not produce a similar antioxidant effect in the pancreas as we previously  
reported [32,33]. Although all the drugs showed a beneficial effect on the histology of the kidney and 
pancreas,  our  previous  findings  [32,33]  as  well  as  these  current  data  seem  to  imply  that  these 
hypoglycemic agents when administered alone might not delay free radical-mediated damage in both 
pancreas and kidneys. 
Until now, an intensive treatment of hyperglycemia is thought to be of immense benefits in both 
type 1 and type 2 diabetic patients [34,35]. However, recent findings have proved otherwise [36]. 
Ismail-Beigi  and  his  colleagues  carried  out  a  study  where  they  investigated  the  effect  of  
intensively-treated  hyperglycemia  on  the  rate  of  microvascular  complications  in  type  2  diabetic 
patients [36]. Besides hypoglycemia and weight gain, they discovered that mortality was higher in the 
intensive treatment group than in the standard group. Hence, intensive treatment was discontinued 
before the end of the study while patients were transitioned to the standard group. In light of these Int. J. Mol. Sci. 2011, 12                       
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remarkable findings, it can be speculated that the higher mortality rate in the intensively-treated group 
may further corroborate the ineffectiveness, limitations and toxicities of these hypoglycemic drugs in 
the  management  of  diabetes  mellitus.  Their  findings  also  lend  credence  to  the  notion  that  the 
management  of  diabetes  mellitus  and  its  complications  should  not  be  restricted  to  hyperglycemia 
alone. Taken together, the relevance of our findings is that it is high time clinical studies involving a 
combination  of  metformin  or  glibenclamide  and  specific  antioxidants  were  performed.  The 
hypoglycemic effect of tualang honey as reported earlier [14] coupled with its potentially protective 
effects on the pancreas [15,32,33] and kidneys against oxidative damage would appear to make it a 
suitable candidate for such adjunctive use.  
3. Materials and Methods 
3.1. Animals and Chemicals 
The study protocol was approved by the Animal Ethics Committee of Universiti Sains Malaysia. 
All animal procedures were performed in strict compliance with the Institutional Guidelines for the 
Care and Use of Animals for Scientific Purposes and in accordance with the Recommendations from 
Helsinki Declaration. Male Sprague-Dawley rats aged 12–14 weeks were used in this study. The rats 
were  obtained  from  the  Laboratory  Animal  Research  Unit  of  Universiti  Sains  Malaysia,  Health 
Campus, Kelantan, Malaysia. They were acclimatized to a well ventilated animal room at 25 ±  2 ° C 
with 12-h light/12-h dark cycles for at least a week prior to the experiment. All animals were supplied 
with commercial pellet food and water ad libitum. 
Streptozotocin,  glibenclamide,  thiobarbituric  acid  (TBA),  dimethyl  sulfoxide  and  glutathione 
reductase  were  obtained  from  Sigma–Aldrich  (St.  Louis,  MO,  U.S.).  GSH:GSSG  assay  kit  was 
purchased from Calbiochem (CA, U.S.). Superoxide dismutase and glutathione peroxidase assay kits 
were  purchased  from  Cayman  (MI,  U.S.).  Bio-Rad  protein  assay  kit  was  purchased  from  
Bio-Rad (U.S.). All other chemicals used were of analytical grade obtained from commercial sources.  
Tualang honey (AgroMas
®, Malaysia) was supplied by Federal Agricultural Marketing Authority 
(FAMA), Kedah, Malaysia. The honey has the following composition: total reducing sugar (67.5%) 
[fructose (29.6%), glucose (30.0%), maltose (7.9%); fructose/glucose ratio (0.99)], sucrose (0.6%) and 
water (20.0%). The dose (1.0 g/kg body weight) was chosen based on our previous study [13]. The 
honey  was  diluted  with  distilled  water  and  prepared  freshly  each  time  it  was  administered. 
Glibenclamide  and  metformin  were  dissolved  in  dimethyl  sulfoxide  (DMSO)  and  distilled  water, 
respectively, before administration. 
3.2. Induction of Experimental Diabetes 
Diabetes was induced in overnight fasted rats by a single intraperitoneal injection of STZ in a 0.1 M 
sodium citrate buffer (pH 4.5). The age-matched control rats received an equivalent amount of citrate 
buffer. Food and water intake were closely monitored daily after STZ administration. The development 
of hyperglycemia in rats was confirmed by measurement of fasting (16 h) blood glucose 48 h after 
STZ administration with the aid of a portable glucometer (Accu-Chek, Roche, Germany) using a drop 
of blood from the tail vein. The animals showing fasting blood glucose level ≥14.0 mmol/L with other Int. J. Mol. Sci. 2011, 12                       
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symptoms  of  diabetes  mellitus  such  as  polyphagia,  polydipsia,  polyuria,  and  weight  loss  were 
considered diabetic and included in the study. 
3.3. Treatment 
The animals were randomly divided into ten groups. Each  group comprised five to seven rats. 
Distilled  water,  tualang  honey,  glibenclamide,  metformin or their  combinations were  administered 
once daily by oral gavage for 4 weeks as follows:  
Group 1:   Non-diabetic + Distilled water (0.5 mL) 
Group 2:   Non-diabetic + Tualang honey (1.0 g/kg body weight) 
Group 3:   Diabetic + Distilled water (0.5 mL) 
Group 4:   Diabetic + Tualang honey (1.0 g/kg body weight) 
Group 5:   Diabetic + Metformin (100 mg/kg body weight) 
Group 6:   Diabetic + Metformin (100 mg/kg body weight) + Tualang honey (1.0 g/kg body weight) 
Group 7:   Diabetic + Glibenclamide (0.6 mg/kg body weight) 
Group 8:   Diabetic + Glibenclamide (0.6 mg/kg body weight) + Tualang honey (1.0 g/kg body weight) 
Group 9:   Diabetic + Glibenclamide (0.6 mg/kg body weight) + Metformin (100 mg/kg body weight) 
Group 10:  Diabetic + Glibenclamide (0.6 mg/kg body weight) + Metformin (100 mg/kg body weight) 
+ Tualang honey (1.0 g/kg body weight) 
Fasting blood glucose and body weight were measured weekly. After 4 weeks of treatment, the 
animals were fasted overnight and sacrificed by decapitation. The kidneys were excised and processed. 
3.4. Processing of Tissues 
The left kidney was rapidly excised, washed in ice-cold normal saline, blotted, frozen in liquid 
nitrogen, and stored at −80 ° C until use. Similarly, the right kidney and pancreas were excised, fixed in 
10% formaldehyde, and dehydrated in ascending grades of ethanol, cleaned in xylene and embedded in 
paraffin. Sections (5 mm thick) were cut and stained with hematoxylin and eosin (H&E) before the 
slides  were  subjected  to  photomicroscopic  observation.  Digital  images  were  obtained  from  a  
high-resolution  digital  camera  system  (Penguin  150CL,  Pixera,  Los  Gatos,  CA,  U.S.)  linked  to  a 
microscope (BX41, Olympus, Tokyo, Japan) and desktop computer (Pentium 4, 2.0 GHz). Images of 
glomeruli at 100×  magnification were digitized. 
Frozen  kidneys  were  thawed  and  homogenized  to  make  10%  homogenate  (w/v)  in  ice-cold  
Tris-HCl (0.1 M, pH 7.4) using an ice-chilled glass homogenizing vessel in a homogenizer fitted with 
Teflon pestle (Glas-Col, U.S.) at 900 rpm. The homogenates were centrifuged at 1000 ×  g for 10 min 
at 4 °C  in a refrigerated centrifuge to remove the nuclear debris. The resulting supernatants were used 
for the assay of total protein, levels of MDA, activities of enzymatic and non-enzymatic antioxidants.  
3.5. Assay of Reduced and Oxidized Glutathione  
Reduced and oxidized glutathione as well as reduced: oxidized glutathione (GSH:GSSG) ratio were 
estimated using Calbiochem GSH:GSSG ratio kit according to the manufacturer's instructions. Briefly, 
the  kidney  homogenates  were  deproteinized  in  5%  metaphosphoric  acid,  centrifuged  and  the Int. J. Mol. Sci. 2011, 12                       
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glutathione  contents  of  the  supernatants  were  measured  by  the  rate  of  colorimetric  change  of  
5,5’-dithiobis(nitrobenzoic acid) at 412 nm in the presence of glutathione reductase and NADPH.  
3.6. Superoxide Dismutase (SOD) Assay 
Superoxide dismutase (SOD) activity was measured using Cayman (MI, U.S.) assay kit according 
to  the  manufacturer’s  instructions.  This  assay  kit  utilizes  a  tetrazolium  salt  for  the  detection  of 
superoxide radicals generated by xanthine oxidase and hypoxanthine. One unit of SOD is defined as 
the  amount of  enzyme  needed to  exhibit 50%  dismutation of  superoxide radical. The SOD  assay 
measures all the three types of SOD (Cu/Zn, Mn, and FeSOD). 
3.7. Glutathione Peroxidase (GPx) Assay 
Glutathione peroxidase (GPx) activity was measured using Cayman (MI, U.S.) assay kit according 
to manufacturer’s instructions. This kit measures GPx activity indirectly by a coupled reaction with 
glutathione reductase (GR). Oxidized glutathione (GSSG), produced upon reduction of hydroperoxide 
by GPx, is recycled to its reduced state by GR and NADPH. The oxidation of NADPH is accompanied 
by a decrease in absorbance at 340 nm. One unit of GPx is defined as the amount of enzyme that 
catalyzes the oxidation of 1 nmol of NADPH per minute at 25 C. 
3.8. Catalase (CAT) Assay 
CAT activity was measured according to the method of Goth [37]. Briefly, this assay involves the 
incubation of 0.5ml of hydrogen peroxide and 0.1 mL of kidney homogenate in a sample test tube. 
After incubation at 37 ° C for 60 sec, the enzymatic reaction was stopped by addition of 0.5 mL of 
ammonium molybdate solution. The yellow complex of ammonium molybdate and hydrogen peroxide 
was then measured spectrophotometrically at 405 nm. One unit of CAT was defined as the amount of 
enzyme that catalyzes the decomposition of 1 µmol of hydrogen peroxide per minute. 
3.9. Glutathione Reductase (GR) Assay 
Glutathione  reductase  (GR)  activity  was  assayed  according  to  the  method  of  Goldberg  and  
Spooner [38]. Briefly, 1 mL of 2.728 mM GSSG solution and 40 µL of kidney homogenate were 
incubated for 5 min at 37 ° C. After incubation, the reaction was initiated by addition of 200 µL of 
1.054 mM  NADPH  solution.  The  decrease  in  absorbance  was  measured  at  340 nm  using  a 
spectrophotometer and recorded every 30 sec over a period of 5 min. GR activity was expressed as unit 
per mg protein based on molar extinction coefficient of 6.22 ×  10
3 L mol
−1 cm
−1. One unit of GR was 
defined as the amount of enzyme that catalyzes the oxidation of 1 nmol of NADPH per minute.  
3.10. Glutathione-S-Transferase (GST) Assay 
Glutathione-S-transferase (GST) activity was assayed according to the method of Habig et al. [39]. 
Briefly, 2 mL of 0.3 M potassium phosphate buffer (pH 6.35), 75 µL of 30 mM CDNB solution, 
725 µL of distilled water and 0.1 mL of kidney homogenate were pipetted into a test tube. The test 
tube was mixed using a vortex and incubated at 37 ° C for 10 min. After incubation, the reaction was Int. J. Mol. Sci. 2011, 12                       
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initiated by addition of 100 µL of 30 mM reduced glutathione solution. The decrease in absorbance 
was measured spectrophotometrically at 340 nm and recorded every 30 sec for 4 min. GST activity 
was calculated as unit per mg protein based on a molar extinction coefficient of 9.6 ×  10
3 L mol
−1 cm
−1. 
One unit of GST was defined as the amount of enzyme that catalyzes the conjugation of 1 nmol of 
GSH-CDNB per minute. 
3.11. Lipid Peroxidation Assay 
The extent of lipid peroxidation was determined as the concentration of malondialdehyde (MDA) 
according to the method of Ohkawa et al. [40]. Briefly, 100 µL of kidney homogenates or MDA 
standards were pipetted into test tubes containing 1.5 mL of 20% (w/v) glacial acetic acid (pH 3.5), 
200 µL of 8.1% (w/v)  sodium dodecyl sulphate (SDS), 1.5 mL of 0.8% (w/v) thiobarbituric acid 
(TBA) and 700 µL of distilled water. The test tubes were incubated at 95 ° C for 60 min with a marble 
on top of each test tube. After incubation, the test tubes were cooled and then centrifuged at 3000 ×  g 
for 10 min. The amount of malondialdehyde (MDA) formed was measured spectrophotometrically at 
532  nm.  1,1,3,3-Tetraethoxypropane  (TEP),  a  form  of  MDA,  was  used  as  standard  in  this  assay. 
TBARS concentration was expressed as nmol of malondialdehyde (MDA) per mg protein. 
3.12. Total Antioxidant Status (TAS) Assay 
TAS was measured according to the method of Koracevic et al. [41]. Briefly, 10 µL of kidney 
homogenate was pipetted in a test tube containing 0.49 mL of 100 mM sodium phosphate buffer. This 
was followed by the addition of 0.5 mL of 10 mM sodium benzoate solution, 0.2 mL of Fe-EDTA 
mixture prepared  from 2 mM EDTA solution and 2 mM Fe(NH4)2(SO4)2 solution and 0.2 mL of 
10 mM H2O2 solution. Each sample had its own control (blank) in which 1 mL of 20% acetic acid was 
added followed by the addition 0.2 mL of Fe-EDTA mixture and 0.2 mL of 10 mM H2O2. Negative 
control was also prepared. After the reagents were added, the test tubes were vortexed and incubated at 
37 °C  for 60 min. This was followed by the addition of 1 mL of 20% acetic acid (sample test tubes 
only)  and TBA. The reaction  tubes  were incubated at 100 °C   for 10 min.  After cooling to room 
temperature, the absorbance was measured spectrophotometrically at 532 nm against distilled water. 
TAS in the kidney homogenates was calculated using uric acid as standard.  
3.13. Protein Assay 
Protein concentration was estimated using a Bio-Rad protein assay kit based on the method of 
Bradford [42]. The assay is a dye-binding assay in which a differential color change of a dye, with 
maximum absorbance at 595 nm, occurs in response to various concentrations of protein. 
3.14. Statistical Analysis 
Data were analyzed using SPSS 18.0.1. The data are expressed as median (interquartile range). 
Groups were compared by Kruskal-Wallis H test. Differences between two groups were identified by 
Mann-Whitney U test followed by Bonferonni’s correction.  Int. J. Mol. Sci. 2011, 12                       
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4. Conclusions  
These data suggest that the hypoglycemic drugs, metformin or glibenclamide, when administered 
alone might not efficiently arrest oxidative stress mediated damage in the kidneys of diabetic rats. Our 
findings demonstrate the beneficial role of tualang honey as an adjunct to metformin or glibenclamide 
in  ameliorating  oxidative  stress  in  the  kidneys  of  streptozotocin-diabetic  rats.  Further  studies  are 
needed in human subjects to determine if these results can be appropriately extrapolated to human 
diabetes.  This  may  result  in  better  and  more  efficient  management  of  diabetes  mellitus  and  its  
related complications. 
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